NKT Therapeutics accesses BioWa's antibody technology
This article was originally published in Scrip
NKT Therapeutics, a private US firm developing killer T-cell-based therapeutics, has acquired rights to use BioWa's antibody efficacy and potency-enhancing technology for undisclosed terms.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.